Betamethasone Valerate, Clotrimazole, Gentamicin Sulfate

Verify with FDA CVM →

229 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
229
Total Reports
9
Deaths Reported
390.0%
Death Rate

Active Ingredients

Betamethasone Valerate, Clotrimazole, Gentamicin Sulfate

Administration Routes

Auricular (Otic)TopicalUnknownOralOphthalmicOtherIntraocular

Species Affected

Dog 198
Unknown 22
Cat 7
Other 1
Human 1

Most Affected Breeds

Crossbred Canine/dog 41
Unknown 24
Retriever - Labrador 16
Pug 11
Maltese 8
Poodle (unspecified) 7
Retriever - Golden 7
Bichon Frise 7
Dog (unknown) 6
Boxer (German Boxer) 6

Most Reported Reactions

Deafness 104
Partial deafness 52
Accidental exposure 11
Depression 9
Missing Cap 7
Ataxia 6
Other ear disorder NOS 6
Diarrhoea 6
Lack of efficacy - NOS 5
Death by euthanasia 5
Pinnal erythema 5
Vials, Leaking 5

Outcome Breakdown

Died
9 (52.9%)
Recovered/Normal
5 (29.4%)
Outcome Unknown
2 (11.8%)
Recovered with Sequela
1 (5.9%)

Data Summary

Metric Value
Total adverse event reports 229
Reports involving death 9
Case-fatality rate (reported events) 390.0%
Distinct species in reports 5
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Betamethasone Valerate, Clotrimazole, Gentamicin Sulfate Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 229 adverse event reports referencing Betamethasone Valerate, Clotrimazole, Gentamicin Sulfate, including 9 reports in which the animal died — a 390.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Betamethasone Valerate, Clotrimazole, Gentamicin Sulfate. Reported administration routes include Auricular (Otic), Topical, Unknown, Oral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Betamethasone Valerate, Clotrimazole, Gentamicin Sulfate reports are Dog (198 reports), Unknown (22 reports), Cat (7 reports), with Dog accounting for the largest share. Within those species, Crossbred Canine/dog (41), Unknown (24), Retriever - Labrador (16) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Betamethasone Valerate, Clotrimazole, Gentamicin Sulfate are Deafness (104), Partial deafness (52), Accidental exposure (11), Depression (9). Of the 17 reports with a coded outcome, Died is the leading category at 52.9%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Betamethasone Valerate, Clotrimazole, Gentamicin Sulfate.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial